Teva raises Copaxone price 10% (#msg-83178715), but this was already baked into Teva’s prior guidance, which implies about $2.9B of US Copaxone sales in 2013 (#msg-81977344).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”